This content was published on Oct 24, 2024 On Thursday, the Swiss Federal Railways presented its first fully renovated InterCity tilting train (ICN). Read more: Swiss railways presents first fully ...

The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer.

U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...

The U.S. Food and Drug Administration has approved Vyloy (zolbetuximab-clzb) in combination with fluoropyrimidine- and ...

Claudin 18.2 testing is a crucial step in determining whether Vyloy will be an effective treatment option for you patients with advanced gastric cancer.

Astellas Pharma Inc. gained U.S. FDA approval of first-in-class claudin 18.2-targeted treatment Vyloy (zolbetuximab-clzb), now indicated as a first-line therapy for adults with locally advanced ...

Seaport Therapeutics Inc. has followed up its recent fundraiser with an oversubscribed $225 million series B financing that will help set it on the path to a phase IIb study of major depressive ...

The FDA has approved Vyloy (zolbetuximab-clzb) in combination with chemotherapy to treat advanced gastric or GEJ cancer.

The regulator’s approval on Friday of Vyloy for gastric or gastroesophageal junction cancer makes it the first and only ...

Astellas Pharma has gained approval from the US Food and Drug Administration (FDA) for VYLOY (zolbetuximab-clzb), in ...

Vyloy is the first CLDN18.2-targeting drug to reach the US market but has already been approved in Japan as well as in the EU ...

The FDA has approved zolbetuximab-clzb (VYLOY) as a first-line targeted therapy, in combination with chemotherapy, for the ...